Celularity reaffirms NEXGEL partnership for biomaterials commercialization

Celularity Inc. (NASDAQ: CELU) restated its strategic commercialization partnership with NEXGEL Inc. (NASDAQ: NXGL) to develop and market placental-derived biomaterials, according to a company statement.

The partnership includes six established commercial products: Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex, which are used in wound care, orthopedics and other medical applications. Three pipeline programs called SPARK, FUSE and ORCHID are also part of the licensing agreement and are pursuing 510(k) medical device regulatory pathways.

Celularity will serve as the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey. The transaction is expected to close by April 15, 2026, subject to customary closing conditions.

"This strategic deal with NEXGEL allows Celularity to focus on a core strength—contract manufacturing—where we have demonstrated over many years our ability to scale and execute cost efficient biomaterial production at a pharmaceutical-like grade," said Robert J. Hariri, Chairman and Chief Executive Officer of Celularity.

Celularity develops regenerative and cellular medicine therapies derived from postpartum placenta materials. The company focuses on treatments targeting aging mechanisms and age-related diseases using both allogeneic and autologous cell therapies.

The partnership aims to capitalize on regulatory and reimbursement developments in the placental-derived biomaterials sector. Financial terms of the agreement were not disclosed in the statement.

You May Also Be Interested In

• Alphabet added to Dow Jones Industrial Average, Verizon dropped
• Upwork secures $150M revolving credit facility with Bank of America
• Clear Secure amends credit agreement, extends maturity to 2031